Logo Tafalgie Therapeutics

Tafalgie Therapeutics,
Research for health &
well-being

The first non-opioid drug for the treatment of chronic, severe or persistent pain, without dependence or tolerance...

Tafalgie Therapeutics is a CNRS and AMU spin-off company engaged in biopharmaceutical research and committed to developing a new scientific approach for next-generation treatments based on a ground-breaking innovation : 

a mechanism of action derived from an endogenous secreted protein capable of modulating pain signals. In the context of the current opioid crisis, we aim to become the key player of reference in the pain field, through the design and proposition of new active pharmaceutical ingredients based on the development of first-in-class polypeptides derived from TAFA4. 

Project chronology
& history

Tafalgie Therapeutics will build on more than ten years of promising scientific research in France

APPROaCH & context

Tafalgie Therapeutics proposes an innovative and effective drug based on an endogenous protein that modulates the transmission of pain information to the brain. 

Pipeline

Tafalgie Therapeutics has developed and identified other new drug candidates.

team of experts

Tafalgie Therapeutics has formed a scientific committee and a supervisory board to assist its management team and the founding partners.

The ambition ?

Become the leader in the field of analgesia with a full range of solutions in a market expected to reach $100bn by 2030.

The mission ?

Provide patients with high-efficacy, high-tolerability, and non-addictive drugs for acute severe pain, as well as for prevention and treatment of chronic refractory pain, in a context marked by the opioid crisis.

AN URGENT GLOBAL NEED TO DEVELOP NEW ANALGESICS :

0
millions

surgical interventions are performed annually

0 %
millions

undergoing surgery experience pain

0
millions

people in Europe suffer from chronic pain.

0 %
patients

do not receive appropriate treatment for their pain.

“ Pain is considered to be the root cause of almost two thirds of medical consultations. For this reason, it is the subject of many studies, both fundamental and clinical.  

Active research on this subject IS absolutely essential to improve our understanding of the mechanisms involved in pain and for the development of new treatments. ”

Site Inserm

Aziz Moqrich explains to Thierry Lhermitte (France Inter) how pain is modulated in the human body.

Listen to our podcast on france Inter